Clinical Trial Update: GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men. [Phase 3]

View source ↗

Summary

Phase 3 GRACE trial update evaluating the effectiveness, safety and tolerability of darunavir/ritonavir in HIV-positive women and men, with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Norvir (ritonavir)
• PREZISTA (darunavir)

Snippet

Sponsor: Tibotec, Inc | Conditions: HIV, Infectious | Phase 3 | Status: COMPLETED | Results posted: 2010-10-19